Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | APC | P25054 | 1/20 | 0.49 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 5/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29914576 | 0.99 | TFPI (0.50) | TFPICTSBAPCQRFPRBACE1 | |
| SCHEMBL29904058 | 0.95 | OPRD1 (0.51) | CTSBBACE1CTSDOPRM1OPRD1 | |
| SCHEMBL29904037 | 0.88 | OPRD1 (0.56) | CTSBQRFPROPRM1OPRD1OPRK1 | |
| SCHEMBL29939679 | 0.88 | APC (0.55) | APCQRFPRBACE1OPRM1OPRD1 | |
| SCHEMBL29512270 | 0.88 | APC (0.55) | APCQRFPRBACE1OPRM1OPRD1 | |
| SCHEMBL31243864 | 0.85 | BACE1 (0.52) | CTSBBACE1CTSD | |
| SCHEMBL29904057 | 0.84 | OPRD1 (0.66) | APCOPRM1OPRD1OPRK1 | |
| SCHEMBL30193614 | 0.84 | OPRD1 (0.56) | CTSBQRFPRCTSDOPRM1OPRD1 | |
| SCHEMBL29664477 | 0.83 | NAALAD2 (0.53) | APCQRFPROPRM1OPRD1 | |
| SCHEMBL31182448 | 0.83 | TFPI (0.60) | TFPIBACE1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111200976-B | Radioactive liquid embolism | 微仙美国有限公司 | 2023-07-07 | — | — | CN | claimed |
| US-12569575-B2 | Radiopaque particle compositions and uses thereof | GUSTAVE ROUSSY TRANSFERT (FR) | 2026-03-10 | — | — | US | disclosed |
| US-20250332261-A1 | Payload-Polymer-Protein Conjugates | GLYKOS FINLAND OY (FI) | 2025-10-30 | — | — | US | disclosed |
| EP-3166638-B1 | PAYLOAD-POLYMER-PROTEIN CONJUGATES | GLYKOS FINLAND OY (FI) | 2025-08-06 | — | — | EP | disclosed |
| US-11992575-B2 | Radioactive liquid embolic | MICROVENTION, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240108781-A1 | POLYMERIC TREATMENT COMPOSITIONS | MICROVENTION, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11801326-B2 | Polymeric treatment compositions | MICROVENTION, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220273825-A1 | RADIOPAQUE PARTICLE COMPOSITIONS AND USES THEREOF | GUSTAVE ROUSSY TRANSFERT (FR) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332261-A1 | Payload-Polymer-Protein Conjugates | TXLNA, DDOST, CD44 | TFPI 1168/4885CTSB 4651/4885APC 1299/4885 |
| US-12569575-B2 | Radiopaque particle compositions and uses thereof | PDGFRB, ERBB2, AKT1 | TFPI 1946/4885CTSB 1284/4885APC 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.